Hims & Hers Health Tumbles on Q2 Miss With 31.9% Float Short
Hims & Hers Health missed Q2 bottom-line consensus estimates as losses widened more than expected, sending shares lower despite a guidance raise for the next period.
Hims & Hers Health Tumbles on Q2 Miss With 31.9% Float Short
NEW YORK, August 11 —
Hims & Hers Health, Inc. (HIMS) reported wider-than-expected Q2 losses, with 31.9% of its float already positioned against the stock.
- Q2 bottom-line losses exceeded consensus estimates; shares fell sharply on the report despite a guidance raise for the next period
- 24.3x forward P/E on 3.8% YoY TTM revenue growth of $2.4bn prices in a reacceleration the market no longer believes
- Next catalyst: Q3 net loss versus the upbeat guidance just issued, and any FDA movement on compounded semaglutide
What Actually Happened
The Q2 result confirmed what a near-record short float had long priced in: losses widened faster than the street expected, and a guidance raise for the next period was not enough to move sentiment. Investors who have followed HIMS recognize the pattern. The detail the wire story misses is $174mn in trailing free cash flow. HIMS is cash-positive on a TTM basis despite trailing EPS of -$0.09, a divergence that points to stock-based compensation and growth investment rather than structural cash destruction. Positive FCF in a company reporting GAAP losses is not noise: it suggests the business is more durable than the income statement implies. The underlying numbers are on the HIMS stock page.
The Catch
A 24.3x forward P/E against 3.8% YoY TTM revenue growth on a $2.4bn base is a valuation that demands a reacceleration story. The only credible engine for that story is GLP-1 and compounded semaglutide, which carries a binary regulatory risk: the FDA's ongoing position on compounded injectables could either validate or shut down that revenue channel before Q3 results land. Buying HIMS at $31.77 means taking a position on an outcome analysts cannot model, in a name where nearly one in three shares is already short.
Bottom Line
The guidance raise is the more interesting signal if management delivers; the market is simply demanding proof before pricing it in. Growth investors with tolerance for regulatory binary risk on GLP-1 will find this setup worth watching; value investors will struggle to justify 24.3x on 3.8% revenue growth. The one number that matters next quarter: net loss versus the upbeat guidance the company just issued. If HIMS beats its own forecast, the short-squeeze math becomes compelling fast, with 31.9% of float still to cover.
For a full analysis with a HOLD rating, read the Basis Report deep dive on Hims & Hers Health.
Current fundamentals, valuation and filing history for Hims & Hers Health, Inc. (HIMS) are tracked on its Basis Report page.
Basis Report is independent research for informational purposes. It is not investment advice and not a recommendation to buy or sell any security.
Hims & Hers reported Q2 2026 results with a bottom-line miss but raised forward guidance, sending shares lower.